These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

446 related items for PubMed ID: 11346863

  • 1. Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment.
    Mundy GR, Yoneda T, Hiraga T.
    Semin Oncol; 2001 Apr; 28(2 Suppl 6):35-44. PubMed ID: 11346863
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Chemical and biological prerequisites for novel bisphosphonate molecules: results of comparative preclinical studies.
    Green JR.
    Semin Oncol; 2001 Apr; 28(2 Suppl 6):4-10. PubMed ID: 11346859
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Death receptor 5 agonist TRA8 in combination with the bisphosphonate zoledronic acid attenuated the growth of breast cancer metastasis.
    Szafran AA, Folks K, Warram J, Chanda D, Wang D, Zinn KR.
    Cancer Biol Ther; 2009 Jun; 8(12):1109-16. PubMed ID: 19652526
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Preclinical evaluation of zoledronate using an in vitro mimetic cellular model for breast cancer metastatic bone disease.
    Dedes PG, Kanakis I, Gialeli Ch, Theocharis AD, Tsegenidis T, Kletsas D, Tzanakakis GN, Karamanos NK.
    Biochim Biophys Acta; 2013 Jun; 1830(6):3625-34. PubMed ID: 23395844
    [Abstract] [Full Text] [Related]

  • 9. Effects of oral UFT combined with or without zoledronic acid on bone metastasis in the 4T1/luc mouse breast cancer.
    Hiraga T, Ueda A, Tamura D, Hata K, Ikeda F, Williams PJ, Yoneda T.
    Int J Cancer; 2003 Oct 10; 106(6):973-9. PubMed ID: 12918079
    [Abstract] [Full Text] [Related]

  • 10. A Phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease.
    Berenson JR, Vescio R, Henick K, Nishikubo C, Rettig M, Swift RA, Conde F, Von Teichert JM.
    Cancer; 2001 Jan 01; 91(1):144-54. PubMed ID: 11148571
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Zoledronic acid in cancer patients with bone metastases: results of Phase I and II trials.
    Berenson JR.
    Semin Oncol; 2001 Apr 01; 28(2 Suppl 6):25-34. PubMed ID: 11346862
    [Abstract] [Full Text] [Related]

  • 13. Bisphosphonates: preclinical review.
    Green JR.
    Oncologist; 2004 Apr 01; 9 Suppl 4():3-13. PubMed ID: 15459425
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Preclinical pharmacology of zoledronic acid.
    Green JR.
    Semin Oncol; 2002 Dec 01; 29(6 Suppl 21):3-11. PubMed ID: 12584689
    [Abstract] [Full Text] [Related]

  • 17. Antitumor effects of bisphosphonates.
    Green JR.
    Cancer; 2003 Feb 01; 97(3 Suppl):840-7. PubMed ID: 12548584
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Bone-related growth factors and zoledronic acid regulate the PTHrP/PTH.1 receptor bioregulation systems in MG-63 human osteosarcoma cells.
    Tenta R, Sourla A, Lembessis P, Koutsilieris M.
    Anticancer Res; 2006 Feb 01; 26(1A):283-91. PubMed ID: 16475708
    [Abstract] [Full Text] [Related]

  • 20. Zoledronic acid: a new parenteral bisphosphonate.
    Li EC, Davis LE.
    Clin Ther; 2003 Nov 01; 25(11):2669-708. PubMed ID: 14693298
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.